Oramed Pharmaceuticals Inc. (ORMP) stock
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.89+0.02 (+0.52%)
Close on Nov 18, 2026Market cap $161.81MP/E 0.9Yield 6.43%
Oramed Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Oramed Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$5.22M. For fiscal 2025 it was -$9.15M. The highest annual figure on record is $4.65M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.15M | – |
| FY2024 | Dec 31, 2024 | -$8.43M | – |
| FY2023 | Dec 31, 2023 | -$10.55M | – |
| FY2021 | Aug 31, 2021 | -$21.56M | – |
| FY2020 | Aug 31, 2020 | -$12.52M | – |
| FY2019 | Aug 31, 2019 | -$12.96M | – |
| FY2018 | Aug 31, 2018 | -$14.66M | – |
| FY2017 | Aug 31, 2017 | -$5.84M | -225.7% |
| FY2016 | Aug 31, 2016 | $4.65M | – |
| FY2015 | Aug 31, 2015 | -$4.95M | – |
| FY2014 | Aug 31, 2014 | -$4.08M | – |
| FY2013 | Aug 31, 2013 | -$3.40M | – |
| FY2012 | Aug 31, 2012 | -$2.30M | – |
| FY2011 | Aug 31, 2011 | -$1.71M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$202.00K | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$2.92M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$468.00K | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$1.63M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$3.54M | -270.5% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$3.52M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$1.92M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$7.11M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $2.08M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$1.48M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$1.42M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$726.00K | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$2.65M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$5.75M | – |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | -$6.17M | – |
| Q3 FY2021CQ2 2021 | May 31, 2021 | -$5.64M | – |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | -$3.28M | – |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | -$6.47M | – |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | -$2.54M | – |
| Q3 FY2020CQ2 2020 | May 31, 2020 | -$3.36M | – |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | -$3.63M | – |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | -$3.00M | – |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | -$3.27M | – |
| Q3 FY2019CQ2 2019 | May 31, 2019 | -$3.66M | – |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | -$4.65M | -168.4% |
| Q3 FY2018CQ2 2018 | May 31, 2018 | -$3.81M | – |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | -$2.05M | -188.2% |
| Q3 FY2017CQ2 2017 | May 31, 2017 | -$2.36M | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | $6.80M | – |
| Q3 FY2016CQ2 2016 | May 31, 2016 | -$2.23M | – |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | $2.32M | – |
| Q1 FY2016CQ4 2015 | Nov 30, 2015 | -$2.25M | – |
| Q4 FY2015CQ3 2015 | Aug 31, 2015 | -$1.03M | – |
| Q3 FY2015CQ2 2015 | May 31, 2015 | -$914.00K | – |
| Q2 FY2015CQ1 2015 | Feb 28, 2015 | -$1.60M | – |
See a number that looks wrong?